Not finding it? Sign in to also search OpenAlex live.
-
Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, J Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
2citations -
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies2022 American Journal of Nephrology article Immunology and Microbiology Complement system in diseases Open access
Carla Nester, Gerald B. Appel, Andrew S. Bomback, Koenraad Peter Bouman, H. Terence Cook, Erica Daina, +14 more
70citations -
Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis2023 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, Jun‐ichi Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
0citations -
Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, +10 more
0citations
8 results